Mechanistically, we found that SERPINA3 may influence the expression of CXCL2 to activate the IL-17 and TNFα signaling pathways, thereby mediating the recruitment of M1 macrophages in the tumor microenvironment and exerting an inhibitory effect on prostate cancer progression. The gene discussed is CXCL2; the disease is neoplasm.